WP
CNTX icon

Woodline Partners’s Context Therapeutics CNTX Stock Holding History

Woodline Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.2K Sell
77,933
-172,155
-69% -$349K ﹤0.01% 1010
2026
Q1 		$655K Buy
+250,088
New +$584K ﹤0.01% 930
2025
Q3 		– Sell
-680,188
Closed -$446K – 908
2025
Q2 		$446K Sell
680,188
-681,000
-50% -$490K ﹤0.01% 862
2025
Q1 		$833K Sell
1,361,188
-162
-0% -$141 0.01% 783
2024
Q4 		$1.43M Buy
1,361,350
+668
+0% +$1.16K 0.01% 707
2024
Q3 		$2.67M Buy
+1,360,682
New +$3.02M 0.02% 446

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Woodline Partners's CNTX Position: Q2 2026 in Review

Woodline Partners reduced its Context Therapeutics (CNTX) stake by 69% in Q2 2026, selling an estimated $349K and leaving 77,933 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Woodline Partners first reported a position in CNTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.67M in Q3 2024. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Woodline Partners held 77,933 shares of Context Therapeutics worth $43.2K as of Q2 2026.
  • Woodline Partners sold 172,155 Context Therapeutics shares in Q2 2026, an estimated $349K.
  • Context Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #1010 holding.
  • Woodline Partners first reported a position in Context Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Woodline Partners's Context Therapeutics position peaked at $2.67M in Q3 2024.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.